Edwards Lifesciences Corporation

EW · NYSE · USD

Historical Earnings

Quarter	Reported	EPS est	EPS act	Surprise	Rev est	Rev act	Surprise	Reaction
Q2 2026	Jul 23, 2026	0.74	0.78	+5.0%	$1.7B	$1.7B	+2.4%	−1.42%
Q1 2026	Apr 23, 2026	0.73	0.78	+7.0%	$1.6B	$1.6B	+3.2%	+5.56%
Q4 2025	Feb 10, 2026	0.62	0.58	−6.1%	$1.5B	$1.6B	+1.5%	+2.96%
Q3 2025	Oct 30, 2025	0.60	0.67	+12.4%	$1.5B	$1.6B	+3.7%	−1.23%
Q2 2025	Jul 24, 2025	0.62	0.67	+7.4%	$1.5B	$1.5B	+3.0%	+5.54%
Q1 2025	Apr 23, 2025	0.60	0.64	+7.4%	$1.4B	$1.4B	+0.9%	+6.63%
Q4 2024	Feb 11, 2025	0.55	0.59	+7.1%	$1.4B	$1.4B	+2.0%	+6.92%
Q3 2024	Oct 24, 2024	0.67	0.67	+0.8%	$1.5B	$1.4B	−12.3%	−1.38%

Detailed View

Q3 2026Nov 4, 2026Q2 2026Jul 23, 2026−1.42%Q1 2026Apr 23, 2026+5.56%Q4 2025Feb 10, 2026+2.96%Q3 2025Oct 30, 2025−1.23%Q2 2025Jul 24, 2025+5.54%Q1 2025Apr 23, 2025+6.63%Q4 2024Feb 11, 2025+6.92%Q3 2024Oct 24, 2024−1.38%Q2 2024Jul 24, 2024Q1 2024Apr 25, 2024Q4 2023Feb 6, 2024

2026 Q2 Metrics

Metric	Estimate	Actual	Surprise	Y/Y
Revenue	$1.7B	$1.7B	Beat +2.40%	+13.6%
EPS	0.74	0.78	Beat +4.98%	+16.4%
Diluted EPS (GAAP)	—	0.42	—	−25.0%

Documents

Earnings call transcript — Q2 2026
Transcript · Jul 23, 2026 · 51 speaker turns
8-K — Q2 2026
8-K · Aug 28, 2026 · sec.gov
10-Q — Q2 2026
10-Q · Aug 4, 2026 · sec.gov
8-K — Q2 2026
8-K · Jul 23, 2026 · sec.gov

Analyst consensus

Buy49 analysts

Bearish · 0 · Hold · 16 · Bullish · 33

Earnings history

	EPS	Estimate
Q3 2024	$0.67	$0.67	Beat
Q4 2024	$0.59	$0.55	Beat
Q1 2025	$0.64	$0.60	Beat
Q2 2025	$0.67	$0.62	Beat
Q3 2025	$0.67	$0.60	Beat
Q4 2025	$0.58	$0.62	Miss
Q1 2026	$0.78	$0.73	Beat
Q2 2026	$0.78	$0.74	Beat

Peers

Company overview

IPO dateMar 27, 2000

CEOBernard J. Zovighian

Employees16,000

SectorHealthcare

IndustryMedical - Devices

CountryUS

ExchangeNew York Stock Exchange

Websitewww.edwards.com

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.